مركب تعزيز انتشار الأكسجين (Arabic Wikipedia)

Analysis of information sources in references of the Wikipedia article "مركب تعزيز انتشار الأكسجين" in Arabic language version.

refsWebsite

Global rank Arabic rank

8doi.org

2^nd place

5^th place

8nih.gov

4^th place

6^th place

3espacenet.com

800^th place

1,795^th place

2web.archive.org

1^st place

2archive.org

6^th place

3^rd place

1clinicaltrials.gov

5,225^th place

3,308^th place

1diffusionpharma.com

low place

archive.org (Global: 6^th place; Arabic: 3^rd place)

Cannon، Joseph G (1999). Pharmacology for Chemists. New York: Oxford University Press. ISBN:978-0841235243.
Starr، Cecie؛ McMillan، Beverly (2012). Human Biology (ط. 9th). ISBN:978-0840061669.

clinicaltrials.gov (Global: 5,225^th place; Arabic: 3,308^th place)

"Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) With Concomitant Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM)". موقع التجارب السريرية. نوفمبر 2011. مؤرشف من الأصل في 2020-08-20. اطلع عليه بتاريخ 2012-09-18.

diffusionpharma.com (Global: low place; Arabic: low place)

investors.diffusionpharma.com

"Diffusion Pharmaceuticals Announces FDA Accelerated Review of TSC Clinical Development Plan to Treat COVID-19 Patients with ARDS". Diffusion Pharmaceuticals. 5 مايو 2020. مؤرشف من الأصل في 2020-08-17. اطلع عليه بتاريخ 2020-05-25.

doi.org (Global: 2^nd place; Arabic: 5^th place)

Gainer, J (2008). "Trans-sodium crocetinate for treating hypoxia/ischemia". Expert Opinion on Investigational Drugs. ج. 17 ع. 6: 917–924. DOI:10.1517/13543784.17.6.917. PMID:18491992.
Gainer J؛ G.M. Chisolm III (1974). "Oxygen diffusion and atherosclerosis". Atherosclerosis. ج. 19 ع. 1: 135–138. DOI:10.1016/0021-9150(74)90049-5. PMID:4810465.
"Biomedical properties of saffron and its potential use in cancer therapy and chemoprevention trials". Cancer Detection and Prevention. ج. 28 ع. 6: 426–432. 2004. DOI:10.1016/j.cdp.2004.09.002. PMID:15582266.
Gainer, J (2008). "Trans-sodium crocetinate for treating hypoxia/ischemia". Expert Opinion on Investigational Drugs. ج. 17 ع. 6: 917–924. DOI:10.1517/13543784.17.6.917. PMID:18491992.
Lapchak P (2010). "Efficacy and safety profile of the carotenoid trans sodium crocetinate administered to rabbits following multiple infarct ischemic strokes: A combination therapy study with tissue plasminogen activator". Brain Research. ج. 1309: 136–145. DOI:10.1016/j.brainres.2009.10.067. PMID:19891959.
Sheehan, Jason؛ وآخرون (2008). "Use of trans sodium crocetinate for sensitizing glioblastoma multiforme to radiation". Journal of Neurosurgery. ج. 108 ع. 5: 972–978. DOI:10.3171/JNS/2008/108/5/0972. PMID:18447715.
Laidig, K.E., J.L. Gainer, V. Daggett (1998). "Altering Diffusivity in Biological Solutions through Modification of Solution Structure and Dynamics". Journal of the American Chemical Society. ج. 120 ع. 36: 9394–9395. DOI:10.1021/ja981656j.{{استشهاد بدورية محكمة}}: صيانة الاستشهاد: أسماء متعددة: قائمة المؤلفين (link)
"Protection against focal ischemic injury to the brain by trans-sodium crocetinate". Journal of Neurosurgery. ج. 113 ع. 4: 802–809. 2010. DOI:10.3171/2009.10.JNS09562. PMC:3380430. PMID:19961314.

espacenet.com (Global: 800^th place; Arabic: 1,795^th place)

worldwide.espacenet.com

US patent 8206751, Gainer J, "New Class of Therapeutics that Enhance Small Molecule Diffusion", issued 2009-04-30
[1]
[2]

nih.gov (Global: 4^th place; Arabic: 6^th place)

pubmed.ncbi.nlm.nih.gov

Gainer, J (2008). "Trans-sodium crocetinate for treating hypoxia/ischemia". Expert Opinion on Investigational Drugs. ج. 17 ع. 6: 917–924. DOI:10.1517/13543784.17.6.917. PMID:18491992.
Gainer J؛ G.M. Chisolm III (1974). "Oxygen diffusion and atherosclerosis". Atherosclerosis. ج. 19 ع. 1: 135–138. DOI:10.1016/0021-9150(74)90049-5. PMID:4810465.
"Biomedical properties of saffron and its potential use in cancer therapy and chemoprevention trials". Cancer Detection and Prevention. ج. 28 ع. 6: 426–432. 2004. DOI:10.1016/j.cdp.2004.09.002. PMID:15582266.
Gainer, J (2008). "Trans-sodium crocetinate for treating hypoxia/ischemia". Expert Opinion on Investigational Drugs. ج. 17 ع. 6: 917–924. DOI:10.1517/13543784.17.6.917. PMID:18491992.
Lapchak P (2010). "Efficacy and safety profile of the carotenoid trans sodium crocetinate administered to rabbits following multiple infarct ischemic strokes: A combination therapy study with tissue plasminogen activator". Brain Research. ج. 1309: 136–145. DOI:10.1016/j.brainres.2009.10.067. PMID:19891959.
Sheehan, Jason؛ وآخرون (2008). "Use of trans sodium crocetinate for sensitizing glioblastoma multiforme to radiation". Journal of Neurosurgery. ج. 108 ع. 5: 972–978. DOI:10.3171/JNS/2008/108/5/0972. PMID:18447715.
"Protection against focal ischemic injury to the brain by trans-sodium crocetinate". Journal of Neurosurgery. ج. 113 ع. 4: 802–809. 2010. DOI:10.3171/2009.10.JNS09562. PMC:3380430. PMID:19961314.

ncbi.nlm.nih.gov

"Protection against focal ischemic injury to the brain by trans-sodium crocetinate". Journal of Neurosurgery. ج. 113 ع. 4: 802–809. 2010. DOI:10.3171/2009.10.JNS09562. PMC:3380430. PMID:19961314.

web.archive.org (Global: 1^st place; Arabic: 1^st place)

"Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) With Concomitant Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM)". موقع التجارب السريرية. نوفمبر 2011. مؤرشف من الأصل في 2020-08-20. اطلع عليه بتاريخ 2012-09-18.
"Diffusion Pharmaceuticals Announces FDA Accelerated Review of TSC Clinical Development Plan to Treat COVID-19 Patients with ARDS". Diffusion Pharmaceuticals. 5 مايو 2020. مؤرشف من الأصل في 2020-08-17. اطلع عليه بتاريخ 2020-05-25.

مركب تعزيز انتشار الأكسجين (Arabic Wikipedia)

archive.org (Global: 6th place; Arabic: 3rd place)

clinicaltrials.gov (Global: 5,225th place; Arabic: 3,308th place)